ÂÜÀòÂÒÂ×

Julian Klein holds a B.Sc. degree in Biotechnology (Germany) and an M.Sc. in Molecular Medicine (Erasmus University, Netherlands). He completed his graduate program at Stanford University where he focused on aging biology and received certification for completion of the Harvard Business School pre-MBA program. The Glenn Foundation for Medical Research has funded his studies on age-related diseases, specifically his work on antisense oligonucleotides targeting muscle stem cells for the treatment of sarcopenia. Previously, he had been involved in the development of a cell-permeable peptide for the treatment of cellular senescence in the context of chronic kidney disease and chemotherapy. His results were published in the prestigious Journal Cell (Baar et at, 2017). The study has drawn worldwide public attention, and ignited a venture-backed company, Cleara Biotech, aiming to bring this peptide to the clinic. Moreover, Mr. Klein identified genomic variants that, today, help clinicians to prognosticate the course of sepsis.